Volume 28 Issue 5, May 2022
Article | 03 March 2022 | Open Access
Immune response to SARS-CoV-2 after a booster of mRNA-1273: an open-label phase 2 trial
A third dose of the COVID-19 vaccine mRNA-1273 is safe and boosts SARS-CoV-2 neutralizing antibody titers almost two-fold higher than the peak levels observed after completion of a two-dose series, highlighting the potential clinical benefit of a booster dose.
Laurence Chu, Keith Vrbicky, Roderick McPhee